ArticleBMC bioinformatics2020
DPDDI: a deep predictor for drug-drug interactions.
Article in BMC bioinformatics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 174 citations in OpenAlex.
- Knowledge mapping of graph neural networks for drug discovery: a bibliometric and visualized analysis.Frontiers in pharmacology · 2024Pooled it
- Beyond Structural Representations: A Semantic-Relational Graph Neural Network for Polypharmacy Side Effect Prediction.Interdisciplinary sciences, computational life sciences · 2026Article
- Knowledge-graph-enhanced multi-scale modeling for drug-drug interaction prediction.Molecular therapy. Nucleic acids · 2026Article
- Advancing Drug-Drug Interaction Prediction with Biomimetic Improvements: Leveraging the Latest Artificial Intelligence Techniques to Guide Researchers in the Field.Biomimetics (Basel, Switzerland) · 2026Review
- A lightweight hybrid deep learning framework for multi-pill detection, multi-attribute recognition, OCR-based imprint analysis, and metadata retrieval.Frontiers in artificial intelligence · 2026Article
- Graph-based deep learning for drug-drug interaction prediction: a systematic review.Frontiers in chemistry · 2026Review
- Research on drug-drug interaction prediction using capsule neural network based on self-attention mechanism.BMC bioinformatics · 2025Article
- Geometry-aware lightweight convolutional network for efficient molecular property prediction.Scientific reports · 2025Article
- PS3N: leveraging protein sequence-structure similarity for novel drug-drug interaction discovery.Scientific reports · 2025Article
- A comprehensive landscape of AI applications in broad-spectrum drug interaction prediction: a systematic review.Journal of cheminformatics · 2025Review
- RCAN-DDI: Relation-aware cross adversarial network for drug-drug interaction prediction.Journal of pharmaceutical analysis · 2025Article
- Graph neural network-based drug-drug interaction prediction.Scientific reports · 2025Article
- LSA-DDI: Learning Stereochemistry-Aware Drug Interactions via 3D Feature Fusion and Contrastive Cross-Attention.International journal of molecular sciences · 2025Article
- Predicting co-word links via heterogeneous graph convolutional networks.Scientific reports · 2025Article
- A novel deep sequential learning architecture for drug drug interaction prediction using DDINet.Scientific reports · 2025Article
- A comprehensive review of deep learning-based approaches for drug-drug interaction prediction.Briefings in functional genomics · 2025Review
- Translational Informatics Driven Drug Repositioning for Neurodegenerative Disease.Current neuropharmacology · 2025Review
- An Enhanced Computational Approach Using Multi-kernel Positive Unlabeled Learning for Predicting Drug-target Interactions.Current computer-aided drug design · 2025Article
- Article
- PSO-FeatureFusion: a general framework for fusing heterogeneous features via particle swarm optimization.Bioinformatics advances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe treatment of complex diseases by taking multiple drugs becomes increasingly popular. However, drug-drug interactions (DDIs) may give rise to the risk of unanticipated adverse effects and even unknown toxicity. DDI detection in the wet lab is expensive and time-consuming. Thus, it is highly desired to develop the computational methods for predicting DDIs. Generally, most of the existing computational methods predict DDIs by extracting the chemical and biological features of drugs from diverse drug-related properties, however some drug properties are costly to obtain and not available in many cases.
resultsIn this work, we presented a novel method (namely DPDDI) to predict DDIs by extracting the network structure features of drugs from DDI network with graph convolution network (GCN), and the deep neural network (DNN) model as a predictor. GCN learns the low-dimensional feature representations of drugs by capturing the topological relationship of drugs in DDI network. DNN predictor concatenates the latent feature vectors of any two drugs as the feature vector of the corresponding drug pairs to train a DNN for predicting the potential drug-drug interactions. Experiment results show that, the newly proposed DPDDI method outperforms four other state-of-the-art methods; the GCN-derived latent features include more DDI information than other features derived from chemical, biological or anatomical properties of drugs; and the concatenation feature aggregation operator is better than two other feature aggregation operators (i.e., inner product and summation). The results in case studies confirm that DPDDI achieves reasonable performance in predicting new DDIs.
conclusionWe proposed an effective and robust method DPDDI to predict the potential DDIs by utilizing the DDI network information without considering the drug properties (i.e., drug chemical and biological properties). The method should also be useful in other DDI-related scenarios, such as the detection of unexpected side effects, and the guidance of drug combination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.